MagForce Nanotechnologies AG Announces Management Team Expansion
(Thomson Reuters ONE) -
MagForce Nanotechnologies AG /
MagForce Nanotechnologies AG Announces Management Team Expansion
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
* Key positions expand internal corporate structures and support Q1 2011 Nano-
Cancer® therapy product launch
* Additional commercialization positions to be filled in the coming weeks
Berlin, November 15, 2010 - MagForce Nanotechnologies AG (FSE:MF6), a leader in
the area of nanotechnology-based cancer treatment, announced today the expansion
of its management team. The new positions, Director of Intellectual Property,
Director of Business/Corporate Development, Director of Finance & Controlling,
and Director of Investor Relations & Corporate Communications, will support both
the upcoming product launch of the company's EU approved therapy for the
treatment of brain tumors and the further development of its Nano-Cancer(®)
therapy in additional cancer indications. MagForce expects its Nano-Cancer(®)
therapy will become available at several leading German cancer centers in the
first quarter of 2011.
"Filling these key company positions is an important step in the transformation
of the company from a research and development only business into a commercial
company. Additional hiring for the sales and marketing team will be completed by
the end of the year," said Dr. Peter Heinrich, CEO of MagForce. "I am extremely
pleased to welcome Dr. Christoph Rehfuess, Dr. Dirk Kautz, Mr. Kajo Wiest, and
Ms. Stacy Wiedenmann to MagForce. Furthermore, Dr. Hans Joachim Hutt is
currently serving as a medical consultant. These individuals bring with them the
experience and expertise to support MagForce as we build commercial
infrastructures and medical networks."
Dr. Christoph Rehfuess joins MagForce as Director of Intellectual Property. As a
qualified European patent attorney with twelve years of management experience in
the biotech intellectual property field at Medigene AG, he will be responsible
for patents, trademarks, and technical contracts.
Dr. Dirk Kautz joins MagForce as Director of Business/Corporate Development and
will support the Management Board in strategic planning. Prior to joining
MagForce, he worked for more than 13 years in the medical devices industry,
holding management positions in marketing and corporate development at, among
others, Nihon Kohden and Biotronik.
Kajo Wiest joins as Director of Finance & Controlling and brings with him more
than 10 years of finance and controlling experience at Jerini AG. During his
time at Jerini, he was responsible for the establishment of controlling
structures as well as supporting the company's IPO and the sale of its wholly-
owned subsidiary JPT, where he served as Finance Manager last year.
Stacy Wiedenmann joins the company as Director of Investor Relations & Corporate
Communications and brings with her over 10 years of experience, including her
experience at Jerini AG, where she headed the same areas from their IPO through
their acquisition.
Dr. Hans Joachim Hutt MD, PhD will support the company in the area of Medical
Affairs. His medical training and over 20 years of experience at leading
pharmaceutical companies, including Boehringer Ingelheim, Sanofi, Bristol-Myers
Squibb, and Sanofi Pasteur MSD, will help MagForce establish commercial networks
and expand its therapeutic applications.
ABOUT MAGFORCE NANOTECHNOLOGIES:
MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based
cancer treatment and the first company worldwide to receive European approval
for a medical product using nanoparticles. Its proprietary procedure, Nano-
Cancer(®) therapy, enables the targeted treatment of solid tumors through the
intratumoral release of heat from magnetic nanoparticles. The company's
products, Nanotherm(®) and NanoActivator(TM), which are the components of the
therapy, received EU-wide regulatory approval as medical devices for the
treatment of brain tumors.
DISCLAIMER:
This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects," "aims," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," or "will". Such forward-
looking statements are based on our current expectations and certain assumptions
which may be subject to a variety of risks and uncertainties. The results
actually achieved by MagForce Nanotechnologies AG may substantially differ from
these forward-looking statements. MagForce Nanotechnologies AG assumes no
obligation to update these forward-looking statements or to correct them in case
of developments which differ from those anticipated. MagForce, Nanotherm,
NanoActivator and Nano-Cancer are trademarks of MagForce Nanotechnologies AG in
selected countries.
For questions, please contact:
Stacy Wiedenmann
Director, Investor Relations & Corporate Communications
Magforce Nanotechnologies AG
Max-Dohrn-Str. 8
10589 Berlin
T +49 30 308 380 31
F +49 30 308 380 99
M +49 151 12000 722
email:swiedenmann(at)magforce.com
www.magforce.com
[HUG#1462493]
--- End of Message ---
MagForce Nanotechnologies AG
Max-Dohrn-Str. 8 Berlin Germany
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce Nanotechnologies AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 15.11.2010 - 11:26 Uhr
Sprache: Deutsch
News-ID 48776
Anzahl Zeichen: 6534
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 350 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MagForce Nanotechnologies AG Announces Management Team Expansion"
steht unter der journalistisch-redaktionellen Verantwortung von
MagForce Nanotechnologies AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
